Wendy Dwyer Net Worth

Wendy Dwyer biography

Wendy Dwyer is Chief Business Officer of the Company. Prior to joining us, Ms. Dwyer served as Chief Business Officer at Portal Instruments from July 2017 to March 2019. Prior to that, Ms. Dwyer served as the Vice President of Corporate Business Development at Ipsen BioScience from July 2014 to January 2017, Business Development Director at AstraZeneca from November 2011 to July 2014, and held senior positions at Endo Pharmaceuticals (formerly Indevus Pharmaceuticals), from September 1998 to January 2010, most recently as Vice President of Business Development. Ms. Dwyer received her M.S. in Management from Lesley University and her B.S. in Psychology from Endicott College.

How old is Wendy Dwyer?

Wendy Dwyer is 46, she's been the Chief Business Officer of Surface Oncology Inc since 2019. There are 11 older and 4 younger executives at Surface Oncology Inc. The oldest executive at Surface Oncology Inc is Elliott Sigal, 68, who is the Independent Director.

What's Wendy Dwyer's mailing address?

Wendy's mailing address filed with the SEC is C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE, MA, 02139.

Insiders trading at Surface Oncology Inc

Over the last 6 years, insiders at Surface Oncology Inc have traded over $69,198,912 worth of Surface Oncology Inc stock and bought 2,836,996 units worth $42,496,090 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Surface Oncology Inc executives and independent directors trade stock every 37 days with the average trade being worth of $156,856. The most recent stock trade was executed by Alison Oneill on 1 August 2023, trading 7,042 units of SURF stock currently worth $6,619.

What does Surface Oncology Inc do?

surface oncology was created to advance next‐generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno‐biology. the company’s scientific founders and sab are comprised of world‐leading immunologists and cancer researchers, including co‐chairs sasha rudensky (memorial sloan kettering) and arlene sharpe (harvard/dfci). they are joined on the sab by christopher hunter and john wherry (university of pennsylvania), carla rothlin (yale university), elliott sigal, and john stagg (university of montreal). surface oncology recently completed a $35 million series a financing round with a-list backers. atlas venture, which seeded the company in 2014, led the round, joined by new enterprise associates, fidelity biosciences, lilly ($lly) ventures, amgen ($amgn) ventures, novartis ($nvs) institute for biomedical research, and elliott sigal, the former head of r&d at bristol-myers. for more information, visit ww

Surface Oncology Inc executives and stock owners

Surface Oncology Inc executives and other stock owners filed with the SEC include:

• J. Jeffrey Goater,
  President, Chief Executive Officer, Director
• Vito Palombella,
  Chief Scientific Officer
• Robert Ross,
  Chief Medical Officer
• J. Jeffrey Goater,
  CEO, Pres & Director
• Dr. Robert W. Ross,
  Chief Medical Officer
• Daniel Lynch,
  Executive Chairman of the Board
• Laurie Stelzer,
  Independent Director
• Cameron McDonough,
  Independent Director
• Armen Shanafelt,
  Independent Director
• David Grayzel,
  Independent Director
• Elliott Sigal,
  Independent Director
• Ramy Ibrahim,
  Independent Director
• Liisa Nogelo,
  Chief Legal Officer, Secretary
• Wendy Dwyer,
  Chief Business Officer
• Jessica Fees,
  Principal Financial Officer, Principal Accounting Officer, Senior Vice President, Finance and Treasurer
• Alison O'Neill,
  Sr. VP of Clinical Devel.
• Bob Steininger,
  Sr. VP of Chemistry, Manufacturing & Controls
• Lisa McGrath,
  Sr. VP of HR
• Liisa I. Nogelo,
  Sec., Chief Compliance Officer & Chief Legal Officer
• Jessica Fees,
  Sr. VP of Fin. & Treasurer
• Carsten Brunn,
  Director
• Theresa Boni,
  General Counsel & Secretary
• Enterprise Associates 14, L...,
  
• Ravi Viswanathan,
  10% owner
• Scott D Sandell,
  10% owner
• Patrick J Kerins,
  10% owner
• Forest Baskett,
  10% owner
• M James Barrett,
  10% owner
• Institutes For Bio Medical ...,
  
• Venture Fund Ix, L.P.Atlas ...,
  
• Management Group, Llc Lilly...,
  
• Peter W. Sonsini,
  10% owner
• David M Mott,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Peter J Barris,
  10% owner
• Enterprise Associates 14, L...,
  10% owner
• 2017 Liquidating Trust Kear...,
  
• Llc Fmr,
  
• Ltd Fil,
  
• Geoff Mcdonough,
  Director
• Capital, Llc Eco R1,
  10% owner
• Alison Oneill,
  Chief Medical Officer
• Henry C. Rath,
  Chief Business Officer
• Denice Torres,
  Director
• Benjamin Hickey,
  Director
• Chandra Adams,
  Deputy GC